Akira Saheki

In Vivo and in Vitro Blood–Brain Barrier Transport of 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors

Akira Saheki, Tetsuya Terasaki, Ikumi Tamai et al. · Pharmaceutical Research · 1994 · 206 citations

In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier

Atsushi Sakata, Ikumi Tamai, Kouichi Kawazu et al. · Biochemical Pharmacology · 1994 · 143 citations

Signal Transduction, Biochemistry, Neurophysiology +10

Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.

Ai Tsuji, Akira Saheki, Ikumi Tamai et al. · Journal of Pharmacology and Experimental Therapeutics · 1993 · 107 citations

A nanometer lipid emulsion, lipid nano-sphere (LNS®), as a parenteral drug carrier for passive drug targeting

Junzo Seki, Satoru Sonoke, Akira Saheki et al. · International Journal of Pharmaceutics · 2004 · 100 citations

Nanoparticles, Nanomedicine, Lipid Preparation +9

Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commercial lipid-based formulations

Hiroshi Fukui, Tomohiro Koike, Takashi Nakagawa et al. · International Journal of Pharmaceutics · 2003 · 52 citations

Lipid Preparation, Nanomedicine, Commercial Lipid-based Formulations +10